Objectives: To review clinical characteristics, treatment, outcome and prognostic factors in dogs with solid cancer-bearing bone metastases.Materials and Methods: Records were reviewed from dogs with histologically-proven solid cancer and bone metastases. Clinicopathologic variables, bone metastases characteristics and skeletal-related events were recorded. Endpoints were time to bone metastases and survival.Results: Fifty dogs were included, 20 of them with synchronous and 30 of them with metachronous bone metastases. In the latter group, median time to diagnosis of bone metastases was 210 days (range, 30 to 1835). Most common primary cancer locations included mammary gland (n=6), spleen (n=5) and tonsil (n=5). Most common histotypes were carcinoma (n=32) and hemangiosarcoma (n=10). Nineteen dogs had multiple bones involvement, with humeri and vertebrae more commonly affected. Twenty-four dogs received antitumoural therapy, five symptomatic treatment and 21 were not treated. Overall median survival after bone metastases diagnosis was 30 days (range, 11 to 49); 83% of dogs died because of skeletal-related events. Lack of antitumoural therapy was significantly associated with shorter survival (hazard ratio: 2.7; 95% confidence interval: 1.3 to 5.6) and with increased risk of skeletal-related death (hazard ratio: 3.3; 95% confidence interval: 1.4 to 7.4). Dogs with endocrine/neuroendocrine tumours (odds ratio: 8.8; 95% confidence interval: 1.2 to 63.9), without appendicular metastases (odds ratio: 5.1; 95% confidence interval: 1.0 to 25.8), without extra-skeletal metastases (odds ratio: 5.2; 95% confidence interval: 1.1 to 24.5) and receiving antitumoural therapy (odds ratio: 14.8; 95% confidence interval: 1.7 to 131.4) had an increased chance of surviving more than 100 days.Clinical Significance: Bone metastases in dogs with solid cancers are associated with poor prognosis and a high risk of skeletal-related events. Treatment appears to have an impact on survival.

A retrospective study on bone metastasis in dogs with advanced‐stage solid cancer / C. Agnoli, S. Sabattini, A. Ubiali, E. Battisti, F. Rossi, A. Diana, M.T. Camerino, S. Perfetti, L. Ciammaichella, D. Stefanello, M. Papa, R. Zaccone, L. Marconato. - In: THE JOURNAL OF SMALL ANIMAL PRACTICE. - ISSN 1748-5827. - (2023), pp. 1-7. [Epub ahead of print] [10.1111/jsap.13621]

A retrospective study on bone metastasis in dogs with advanced‐stage solid cancer

A. Ubiali;D. Stefanello;
2023

Abstract

Objectives: To review clinical characteristics, treatment, outcome and prognostic factors in dogs with solid cancer-bearing bone metastases.Materials and Methods: Records were reviewed from dogs with histologically-proven solid cancer and bone metastases. Clinicopathologic variables, bone metastases characteristics and skeletal-related events were recorded. Endpoints were time to bone metastases and survival.Results: Fifty dogs were included, 20 of them with synchronous and 30 of them with metachronous bone metastases. In the latter group, median time to diagnosis of bone metastases was 210 days (range, 30 to 1835). Most common primary cancer locations included mammary gland (n=6), spleen (n=5) and tonsil (n=5). Most common histotypes were carcinoma (n=32) and hemangiosarcoma (n=10). Nineteen dogs had multiple bones involvement, with humeri and vertebrae more commonly affected. Twenty-four dogs received antitumoural therapy, five symptomatic treatment and 21 were not treated. Overall median survival after bone metastases diagnosis was 30 days (range, 11 to 49); 83% of dogs died because of skeletal-related events. Lack of antitumoural therapy was significantly associated with shorter survival (hazard ratio: 2.7; 95% confidence interval: 1.3 to 5.6) and with increased risk of skeletal-related death (hazard ratio: 3.3; 95% confidence interval: 1.4 to 7.4). Dogs with endocrine/neuroendocrine tumours (odds ratio: 8.8; 95% confidence interval: 1.2 to 63.9), without appendicular metastases (odds ratio: 5.1; 95% confidence interval: 1.0 to 25.8), without extra-skeletal metastases (odds ratio: 5.2; 95% confidence interval: 1.1 to 24.5) and receiving antitumoural therapy (odds ratio: 14.8; 95% confidence interval: 1.7 to 131.4) had an increased chance of surviving more than 100 days.Clinical Significance: Bone metastases in dogs with solid cancers are associated with poor prognosis and a high risk of skeletal-related events. Treatment appears to have an impact on survival.
Settore VET/08 - Clinica Medica Veterinaria
Settore VET/09 - Clinica Chirurgica Veterinaria
Settore VET/03 - Patologia Generale e Anatomia Patologica Veterinaria
2023
27-apr-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
Post print Bone Metastasis JSAP.pdf

Open Access dal 28/04/2024

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 183.5 kB
Formato Adobe PDF
183.5 kB Adobe PDF Visualizza/Apri
J of Small Animal Practice - 2023 - Agnoli - A retrospective study on bone metastasis in dogs with advanced‐stage solid.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 224.91 kB
Formato Adobe PDF
224.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/988648
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact